Skip to main content
. 2019 Jul 1;10:2901. doi: 10.1038/s41467-019-10681-4

Fig. 8.

Fig. 8

Ezh2 is required for ErbB2-driven mammary epithelial transformation. a Kaplan–Meier analysis of mammary tumor onset in MMTV-NIC mice with wild-type Ezh2 alleles (NIC/Ezh2+/+) and mice heterozygous (NIC/Ezh2+/L) or homozygous (NIC/Ezh2L/L) for the conditional Ezh2 allele. Inset table shows group sizes (n), average time to tumor onset and penetrance of mammary tumors. b Immunofluorescence (IF) analysis of ErbB2 and Ezh2 expression in mammary glands from 16 week-old NIC/Ezh2+/+ and NIC/Ezh2L/L mice. c IF analysis of ErbB2 and Ki67 expression in mammary glands from 16 week-old NIC/Ezh2+/+ and NIC/Ezh2L/L mice. d Quantification of Ki67-positive nuclei in ErbB2-expressing cells in mice of both genotypes. Data in (bd) represent analyses of 4 independent mice per genotype, 5 fields of view per mammary gland. All scale bars represent 50 µm. e Hematoxylin-stained, whole-mounted mammary glands from MMTV-NIC mice treated for 10 weeks with GSK126 or vehicle control. White arrows indicate transformed mammary epithelial lesions. Scale bar indicates 500 µm. f IF analysis of ErbB2 and Ki67 expression in mammary glands from MMTV-NIC mice treated for 10 weeks with GSK126 or vehicle control. Scale bar indicates 100 µm. g Quantification of Ki67-positive nuclei in ErbB2-expressing cells in mice as in (f) (n = 6 per treatment group). In all scatter plots, the center line indicates the mean and error bars are ±SEM, with * = p < 0.05 (unpaired, two-tailed Student’s t-test)